Rachel L. Shapiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rachel L. Shapiro has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Laura M. Ensign
Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, USA
2 shared publications Davell M. Carter
Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
1 shared publication- Davell M. Carter
The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, USA
1 shared publication Eliza Duggan
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, USA
1 shared publicationHannah C. Zierden
Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
1 shared publication- Hannah C. Zierden
Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742
1 shared publication
Latest Publications
- 15 May 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (2) , 609-620
Locally administered nanosuspension increases delivery of estradiol for the treatment of vaginal atrophy in mice
Vaginal atrophy affects up to 57% of post-menopausal women, with symptoms ranging from vaginal burning to dysuria. Estradiol hormone replacement therapy may be prescribed to alleviate these symptoms, though many vaginal products have drawbacks including increased discharge and local tissue toxicity due to their hypertonic nature. Here, we describe the development and characterization of a Pluronic F127-coated estradiol nanosuspension (NS) formulation for improved vaginal estradiol delivery. We compare the pharmacokinetics to the clinical comparator vaginal cream (Estrace) and demonstrate increased delivery of estradiol to the vaginal tissue. We utilized ovariectomized (OVX) mice as a murine model of post-menopausal vaginal atrophy and demonstrated equivalent efficacy in vaginal re-epithelialization when dosed with either the estradiol NS or Estrace cream. Further, we demonstrate compatibility of the estradiol NS with vaginal bacteria in vitro. We demonstrate that a Pluronic F127-coated estradiol NS may be a viable option for the treatment of post-menopausal vaginal atrophy. Graphical Abstract
- 15 May 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (2) , 609-620
Locally administered nanosuspension increases delivery of estradiol for the treatment of vaginal atrophy in mice
Vaginal atrophy affects up to 57% of post-menopausal women, with symptoms ranging from vaginal burning to dysuria. Estradiol hormone replacement therapy may be prescribed to alleviate these symptoms, though many vaginal products have drawbacks including increased discharge and local tissue toxicity due to their hypertonic nature. Here, we describe the development and characterization of a Pluronic F127-coated estradiol nanosuspension (NS) formulation for improved vaginal estradiol delivery. We compare the pharmacokinetics to the clinical comparator vaginal cream (Estrace) and demonstrate increased delivery of estradiol to the vaginal tissue. We utilized ovariectomized (OVX) mice as a murine model of post-menopausal vaginal atrophy and demonstrated equivalent efficacy in vaginal re-epithelialization when dosed with either the estradiol NS or Estrace cream. Further, we demonstrate compatibility of the estradiol NS with vaginal bacteria in vitro. We demonstrate that a Pluronic F127-coated estradiol NS may be a viable option for the treatment of post-menopausal vaginal atrophy. Graphical Abstract
- 1 July 2021
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 174, 190-209
Next generation strategies for preventing preterm birth
- 1 July 2021
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 174, 190-209
Next generation strategies for preventing preterm birth